Adjunctive Ganaxolone (GNX) Treatment In Children And Adults With Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC)
Rochester, MN
The purpose of this trial is to assess the safety and effectiveness of Ganaxolone (GNX) compared to placebo as adjunctive therapy for seizures associated with Tuberous Sclerosis Complex (TSC) in children and adults as assessed by the change from baselinea in the frequency of countable major motor and focal seizures (primary endpoint seizuresb) during the double-blind phase.